| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
Form 4: Spandow Oliver J., Director
Received 3,916 shares as a grant or award |
| 12 Nov 2026 |
Form 4: Amron Arthur H, Director
Received 3,514 shares as a grant or award |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 |
| 05 Nov 2026 | 10-Q |
| 14 Oct 2026 |
Proxy statement: annual meeting on October 12, 2026
CEO pay $627K, up 53% · say-on-pay vote |
| 13 Oct 2026 |
8-K: Shareholder Director Nominations; Other Events
Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 |
| 16 Sep 2026 | SCHEDULE 13D/A |
| 16 Sep 2026 | SCHEDULE 13G |
| 16 Sep 2026 |
Form 4: Wexford Capital Lp, 10% owner and 3 others
Disposed of 3,377,821 shares (Other Transaction) |
| 16 Sep 2026 |
Form 4: Amron Arthur H, Director and 1 other
Acquired 43,295 shares (Other Transaction) |
| 20 Aug 2026 |
Form 4: Wexford Capital Lp, 10% owner and 3 others
Received 812 shares by exercise or conversion ($2.92K) |
| 14 Aug 2026 |
Form 4: Amron Arthur H, Director
Received 2,418 shares as a grant or award |
| 10 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 |
| 12 Jun 2026 |
Form 4: Amron Arthur H, Director
Received 3,574 shares as a grant or award |
| 15 Jun 2026 |
8-K: Regulation FD Disclosure
On June 12, 2026, Nephros, Inc. (the “Company”) posted an updated 2026 Corporate Presentation on its corporate website. A copy of this presentation is furnished herewith as Exhibit 99.1. |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Nephros Announces Financial Results for Quarter Ended March 31, 2026 |
| 07 May 2026 | 10-Q |
| 30 Apr 2026 | 10-K/A |
Loading...